

# Mirko Farina

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3822873/publications.pdf>

Version: 2024-02-01

40  
papers

503  
citations

949033

11  
h-index

759306

22  
g-index

42  
all docs

42  
docs citations

42  
times ranked

797  
citing authors

#	ARTICLE	IF	CITATIONS
1	How We Manage Myelofibrosis Candidates for Allogeneic Stem Cell Transplantation. <i>Cells</i> , 2022, 11, 553.	1.8	5
2	Genomic profiling identifies somatic mutations predicting thromboembolic risk in patients with solid tumors. <i>Blood</i> , 2021, 137, 2103-2113.	0.6	57
3	RT-qPCR versus Digital PCR: How Do They Impact Differently on Clinical Management of Chronic Myeloid Leukemia Patients?. <i>Case Reports in Oncology</i> , 2021, 13, 1263-1269.	0.3	18
4	Exosomes and Extracellular Vesicles in Myeloid Neoplasia: The Multiple and Complex Roles Played by These "Magic Bullets". <i>Biology</i> , 2021, 10, 105.	1.3	11
5	Molecular response and quality of life in chronic myeloid leukemia patients treated with intermittent TKIs: First interim analysis of OPTiMA study. <i>Cancer Medicine</i> , 2021, 10, 1726-1737.	1.3	9
6	Development of BCR-ABL1 Transgenic Zebrafish Model Reproducing Chronic Myeloid Leukemia (CML) Like-Disease and Providing a New Insight into CML Mechanisms. <i>Cells</i> , 2021, 10, 445.	1.8	4
7	Changes in Stem Cell Transplant activity and procedures during SARS-CoV2 pandemic in Italy: an Italian Bone Marrow Transplant Group (GITMO) nationwide analysis (TransCOVID-19 Survey). <i>Bone Marrow Transplantation</i> , 2021, 56, 2272-2275.	1.3	12
8	The possible role of mutated endothelial cells in myeloproliferative neoplasms. <i>Haematologica</i> , 2021, 106, 2813-2823.	1.7	7
9	CT-290: Clinical Frailty Scale as a Novel Tool to Evaluate Patients' Eligibility for Allogeneic Stem Cell Transplant: A Single-Center Experience on 234 Patients >50 Years Old. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, S452.	0.2	0
10	Poster: CT-290: Clinical Frailty Scale as a Novel Tool to Evaluate Patients' Eligibility for Allogeneic Stem Cell Transplant: A Single-Center Experience on 234 Patients >50 Years Old. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, S258.	0.2	0
11	Comparative Mutational Profiling of Hematopoietic Progenitor Cells and Circulating Endothelial Cells (CECs) in Patients with Primary Myelofibrosis. <i>Cells</i> , 2021, 10, 2764.	1.8	8
12	Postremission therapy with repeated courses of high-dose cytarabine, idarubicin, and limited autologous stem cell support achieves a very good long-term outcome in European leukemia net favorable and intermediate-risk acute myeloid leukemia. <i>Hematological Oncology</i> , 2020, 38, 754-762.	0.8	9
13	CT-027: Multidimensional Geriatric Assessment for Elderly Hematological Patients (>60 years) Submitted to Allogeneic Stem Cell Transplantation; A French-Italian 10-year Experience on 228 Patients. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, S213-S214.	0.2	0
14	Advances in CMV Management: A Single Center Real-Life Experience. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 534268.	1.8	16
15	Case Report: Late Onset of Myelodysplastic Syndrome From Donor Progenitor Cells After Allogeneic Stem Cell Transplantation. Which Lessons Can We Draw From the Reported Case?. <i>Frontiers in Oncology</i> , 2020, 10, 564521.	1.3	5
16	Multidimensional geriatric assessment for elderly hematological patients (>60 years) submitted to allogeneic stem cell transplantation. A French-Italian 10-year experience on 228 patients. <i>Bone Marrow Transplantation</i> , 2020, 55, 2224-2233.	1.3	23
17	<i>ETV6</i> : A Candidate Gene for Predisposition to "Blend Pedigrees"? A Case Report from the NEXT-Family Clinical Trial. <i>Case Reports in Hematology</i> , 2020, 2020, 1-7.	0.3	7
18	Increased Interleukin-8 (IL8)-CXCR2 Signaling Promotes Progression of Bone Marrow Fibrosis in Myeloproliferative Neoplasms. <i>Blood</i> , 2020, 136, 6-7.	0.6	3

#	ARTICLE	IF	CITATIONS
19	The e13a2 BCR $\rightarrow$ ABL transcript negatively affects sustained deep molecular response and the achievement of treatment $\rightarrow$ free remission in patients with chronic myeloid leukemia who receive tyrosine kinase inhibitors. <i>Cancer</i> , 2019, 125, 1674-1682.	2.0	45
20	Digital PCR improves the quantitation of DMR and the selection of CML candidates to TKIs discontinuation. <i>Cancer Medicine</i> , 2019, 8, 2041-2055.	1.3	63
21	Prognostic role of baseline <sup>18</sup> F $\rightarrow$ FDG PET/CT parameters in MALT lymphoma. <i>Hematological Oncology</i> , 2019, 37, 39-46.	0.8	33
22	Comparative Somatic Mutational Profiling of CD34+ Hematopoietic Precursors (HSC) and Circulating Endothelial Cells (CEC) in Patients with Primary Myelofibrosis (PMF). <i>Blood</i> , 2019, 134, 1684-1684.	0.6	3
23	Feasibility of tumor $\rightarrow$ derived exosome enrichment in the onco $\rightarrow$ hematology leukemic model of chronic myeloid leukemia. <i>International Journal of Molecular Medicine</i> , 2019, 44, 2133-2144.	1.8	27
24	Extended Mutational Profiling By MSK-IMPACTTM Identifies Mutations Predicting Thromboembolic Risk in Patients with Solid Tumor Malignancy. <i>Blood</i> , 2019, 134, 633-633.	0.6	1
25	R-Interferon Treatment before Imatinib Reverses the Negative Impact of e13a2 Transcript Type on Treatment Free Remission Duration after Tyrosine Kinase Inhibitors Discontinuation in Chronic Myeloid Leukemia Patients. <i>Blood</i> , 2019, 134, 4146-4146.	0.6	0
26	Short course of bortezomib in anemic patients with relapsed cold agglutinin disease: a phase 2 prospective GIMEMA study. <i>Blood</i> , 2018, 132, 547-550.	0.6	61
27	Identification of a Novel Mutation Predisposing to Familial AML and MDS Syndrome By a NGS Approach. <i>Blood</i> , 2018, 132, 4387-4387.	0.6	1
28	Comparative Monitoring of Minimal Residual Disease (MRD) By RT-Quantitative (RT-qPCR) and Digital PCR (dPCR) in Ph+ Chronic Myeloid Leukemia (CML) Patients Treated with TKIs for Recognition of Stable Deep Molecular Response (DMR) and Identification of Best Candidates to TKIs Treatment Discontinuation. <i>Blood</i> , 2018, 132, 3012-3012.	0.6	1
29	Combining Imatinib-Following-Nilotinib Treatment in First Line Therapy for Chronic Phase Chronic Myeloid Leukemia. Update from the PhiloPhi34 Study at 24 Months of Follow-up. <i>Blood</i> , 2018, 132, 5435-5435.	0.6	0
30	First Interim Report of the Italian Multicentric Phase-III Randomized Study to Optimize TKIs Multiple Approaches - (OPTkIMA) in Elderly Patients (older than 60 years) with Ph+ Chronic Myeloid Leukemia (CML) and MR3.0/ MR4.0 Stable Molecular Response. <i>Blood</i> , 2018, 132, 4251-4251.	0.6	0
31	Adult onset hemophagocytic lymphohistiocytosis prognosis is affected by underlying disease and coexisting viral infection: analysis of a single institution series of 35 patients. <i>Hematological Oncology</i> , 2017, 35, 828-834.	0.8	36
32	Therapeutically targeting $\rightarrow$ SELF $\rightarrow$ reinforcing leukemic niches in acute myeloid leukemia: A worthy endeavor?. <i>American Journal of Hematology</i> , 2016, 91, 507-517.	2.0	21
33	Is Having Clonal Cytogenetic Abnormalities the Same as Having Leukaemia?. <i>Acta Haematologica</i> , 2016, 135, 39-42.	0.7	6
34	The Detection of Minimal Residual Disease By Multiparameter Flow Cytometry Predicts a Higher Risk of Relapse in Patients with ELN Intermediate Risk Acute Myeloid Leukemia Where Molecular Markers Are Not Available. <i>Blood</i> , 2016, 128, 2882-2882.	0.6	0
35	Postremission Therapy with Repeated Courses of HD-Arac, Idarubicin and Limited Autologous Stem Cell Support Achieves a Very Good Long-Term Outcome in ELN Favourable and Intermediate-Risk AML Except in NPM-Mutated Patients Where Relapse May Occur Even after Five Years. <i>Blood</i> , 2016, 128, 3993-3993.	0.6	0
36	A Gene Panel NGS-Based Strategy for Genomic Characterization of Acute Myeloid Leukemias (AMLs). <i>Blood</i> , 2015, 126, 4952-4952.	0.6	0

#	ARTICLE	IF	CITATIONS
37	Can Allo-HSCT Improve the Poor Clinical Outcome of the "Internal Tandem Duplication" of the FLT3 Gene?. Blood, 2014, 124, 5938-5938.	0.6	0
38	Alternative Splicing of hTERT Exon 7 in AML: Biological Fuction and Prognostic Significance. Blood, 2014, 124, 1019-1019.	0.6	0
39	Do Unexpected and Cryptic FISH Lesions Of Chromosomally Normal MDS Patients Have Any Prognostic Relevance?. Blood, 2013, 122, 1549-1549.	0.6	0
40	Results of an Innovative Program for Surveillance, Prophylaxis, and Treatment of Infectious Complications Following Allogeneic Stem Cell Transplantation in Hematological Malignancies (BATMO Protocol). Frontiers in Oncology, 0, 12, .	1.3	8